AmpliPhi Biosciences (APHB) Granted SME Status by EMA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
AmpliPhi Biosciences Granted Small and Medium Enterprise Status by European Medicines Agency
November 1, 2016 8:45 AM EDTSAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced that it has been granted Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA).
SME designation was launched by the EMA to promote innovation and the development of new human therapeutics by early and mid-stage healthcare companies. SME status confers certain benefits on its member companies including financial support and incentives, including significantly reduced fees for regulatory procedures, including Scientific Advice, Marketing Authorizations and inspections, and... More
